
    
      This is a prospective, multicenter phase II trial designed to evaluate the activity of
      Eltrombopag second line treatment in adult patients with primary Immune Thrombocytopenia
      (ITP) not responsive or in relapse after a full first line steroids treatment (prednisone or
      dexamethasone) Â± Intravenous Immune Globulin (IVIG).
    
  